Loading…
BriaCell Therapeutics Corp. is projected to decline to $3.25 by 2027, a -3% move from its current price of $3.36. BCTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $3.24 | $3.36 | $3.48 | -0.05% |
| Aug 6 | $3.19 | $3.36 | $3.54 | -0.09% |
| Aug 7 | $3.15 | $3.36 | $3.57 | -0.14% |
| Aug 8 | $3.12 | $3.35 | $3.61 | -0.18% |
| Aug 9 | $3.09 | $3.35 | $3.64 | -0.23% |
| Aug 10 | $3.06 | $3.35 | $3.66 | -0.27% |
| Aug 11 | $3.04 | $3.35 | $3.69 | -0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.04 | $3.35 | $3.69 | -0.32% |
| Week 2 | $2.91 | $3.34 | $3.83 | -0.64% |
| Week 3 | $2.81 | $3.33 | $3.93 | -0.95% |
| Week 4 | $2.73 | $3.32 | $4.03 | -1.27% |
| Week 5 | $2.66 | $3.31 | $4.11 | -1.58% |
| Week 6 | $2.60 | $3.30 | $4.18 | -1.89% |
| Week 7 | $2.54 | $3.29 | $4.24 | -2.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BriaCell Therapeutics Corp. is a healthcare company described as a pre-clinical stage immuno-oncology company that engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
The company also develops Bria-OTS, a personalized off-the-shelf immunotherapy, and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp.
has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers.
The company is headquartered in West Vancouver, Canada.
BriaCell Therapeutics Corp. (BCTX) is the asset, currently priced at $3.65 per share with a market capitalization of $31.71M and a rank of 4447. The stock sits in the healthcare category and has a defined near-term technical and fundamental outlook based on the provided forecast data.
The near-term forecast shows a neutral stance for 2026, with a 2026 average price of $3.65 and a range from $2.74 to $4.62, returning 0% ROI. The outlook remains neutral through 2029, before turning bullish from 2030 onward, with rising average prices and meaningful upside in the long term.
In the multi-year view, the forecast projects a bullish path from 2030 onward, with the 2030 average price at $4.84 (32.6% ROI), 2040 at $6.88 (88.8% ROI), and 2050 at $14.79 (305.6% ROI). These figures imply substantial long-term upside, albeit with uncertainty inherent to such predictions.
A major floor 29.0% below — a decisive break under it would weaken the trend.
The nearest floor, 13.7% below — buyers have tended to step in here.
The nearest ceiling, 17.3% above — a clean break opens room to run.
A major ceiling 37.5% above — clearing it would confirm fresh momentum.
Key BCTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.50 | Sell | $3.52 | Sell |
| MA 10 | $3.58 | Sell | $3.56 | Sell |
| MA 20 | $3.65 | Sell | $3.55 | Sell |
| MA 50 | $3.37 | Sell | $3.56 | Sell |
| MA 100 | $3.75 | Sell | $4.12 | Sell |
| MA 200 | $5.77 | Sell | $6.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.38 | Neutral |
| Stoch RSI (14) | 8.80 | Buy |
| CCI (20) | -115.91 | Sell |
| Williams %R (14) | -92.59 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -12.69 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 7.41 | Buy |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | 0.11 | Buy |
| Ultimate (7,14,28) | 42.93 | Neutral |
| Momentum (10) | -0.29 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 3.45 | Sell |
| ADX (14) | 12.68 | Neutral |
| ATR (14) | 0.13 | Info |
The near-term technical picture is bullish. The sentiment is listed as BULLISH in the 30-day window.
The RSI(14) is 50, with the 50-day simple moving average at $3.42 and the 200-day simple moving average at $6.18, indicating mixed momentum against a longer-term trend.
Key support is identified at $2.74 and resistance at $3.94. The 30-day price range runs from $2.81 to $4.73, framing potential volatility in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.74 | $3.36 | $4.24 | 0% | Neutral | |
| $2.51 | $3.25 | $4.49 | -3% | Neutral | |
| $2.46 | $3.31 | $4.80 | -1% | Neutral | |
| $2.25 | $3.13 | $4.70 | -7% | Neutral | |
| $2.89 | $4.14 | $6.42 | +23% | Bullish | |
| $3.24 | $4.76 | $7.58 | +42% | Bullish | |
| $2.90 | $4.37 | $7.13 | +30% | Bullish | |
| $2.92 | $4.50 | $7.50 | +34% | Bullish | |
| $2.83 | $4.47 | $7.59 | +33% | Bullish | |
| $2.75 | $4.44 | $7.69 | +32% | Bullish | |
| $3.44 | $6.14 | $11.47 | +83% | Bullish | |
| $5.83 | $12.48 | $25.97 | +272% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.74 | $3.36 | $3.95 | +0.00% |
| September 2026 | $2.62 | $3.13 | $3.86 | -6.91% |
| October 2026 | $2.67 | $3.22 | $4.04 | +3.06% |
| November 2026 | $2.76 | $3.36 | $4.25 | +4.13% |
| December 2026 | $2.71 | $3.31 | $4.24 | -1.34% |
Click any year to see its month-by-month BCTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
BriaCell Therapeutics Corp.'s 2026 outlook centres on $3.36, within a $2.74 to $4.24 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, BCTX could reach as high as $4.49, with a base case around $3.25 and support toward $2.51 — roughly -3% from $3.36. A consolidation phase looks the most probable path here.
Expect BCTX to range from $2.46 to $4.80 through 2028. The $3.31 average target implies a -1% move from current prices. That is up +2% on the projected 2027 average. Price action looks broadly range-bound.
The BCTX price prediction for 2029 points to an average of $3.13 (low $2.25, high $4.70) — a potential decline of -7% on today's $3.36. A consolidation phase looks the most probable path here.
In 2030, BCTX is projected to trade between $2.89 and $6.42, averaging $4.14 — a potential gain of +23% from today's $3.36. That is up +32% on the projected 2029 average. Momentum favours further upside here.
BriaCell Therapeutics Corp.'s 2031 outlook centres on $4.76, within a $3.24 to $7.58 range. That is up +15% on the projected 2030 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, BCTX could reach as high as $7.13, with a base case around $4.37 and support toward $2.90 — roughly +30% from $3.36. Momentum favours further upside here.
Expect BCTX to range from $2.92 to $7.50 through 2033. The $4.50 average target implies a +34% move from current prices. That is up +3% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The BCTX price prediction for 2034 points to an average of $4.47 (low $2.83, high $7.59) — a potential gain of +33% on today's $3.36. Momentum favours further upside here.
In 2035, BCTX is projected to trade between $2.75 and $7.69, averaging $4.44 — a potential gain of +32% from today's $3.36. That is -1% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
BriaCell Therapeutics Corp.'s 2040 outlook centres on $6.14, within a $3.44 to $11.47 range. That is up +38% on the projected 2035 average. That marks a +83% change versus current levels. Momentum favours further upside here.
By 2050, BCTX could reach as high as $25.97, with a base case around $12.48 and support toward $5.83 — roughly +272% from $3.36. Buyers look set to stay in control over this stretch.
Investing $1,000 in BCTX today (≈ 297.619048 BCTX) could be worth
$3,715.71
+$2,715.71 (+272%) by 2050 · US Dollar
Based on the average projected BCTX price of $12.48 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCTXwould be worth at today's price.
$1,000 invested in BCTX on Jul 31, 2025 (≈ 133.333333 BCTX) would be worth
$448
-$552 (-55.2%) today · 0.45× · US Dollar
Based on a BCTX entry price of $7.5 vs. today's $3.36.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.58 | $938.55 | -6.1% |
| 1 month ago | $3.47 | $968.3 | -3.2% |
| 3 months ago | $4.18 | $803.83 | -19.6% |
| 6 months ago | $4.47 | $751.68 | -24.8% |
| 1 year ago | $7.5 | $448 | -55.2% |
| All time (5.0y) ago | $51.7 | $64.99 | -93.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCTX forecast.
Our base-case forecast reaches $6.70 around 2050.
Implied market cap at $6.70: $58.29M
The multi-year forecast shows mixed near-term activity but confirms longer-term upside. In 2026, the average price is $3.65 with a neutral sentiment and 0% ROI, with a low of $2.74 and a high of $4.62.
From 2030 onward, the outlook strengthens into a bullish trajectory: 2030 average $4.84 with a 32.6% ROI; 2040 average $6.88 with an 88.8% ROI; and 2050 average $14.79 with a 305.6% ROI. The 2031–2035 years also show bullish signals with higher averages and double-digit ROI figures in some years, reinforcing a long-term upside potential, alongside the risks typical for early-stage healthcare equities.
These are estimates, not guarantees. Actual results may differ due to factors not reflected in the forecast.
Tap a question to reveal the answer.
2030 average price: $4.84 with a 32.6% ROI and a bullish sentiment. The 2030 max is $7.66 and the min is $3.31.
Near term (2026–2029) shows Neutral sentiment with averages around $3.65 (2026) and declines to $3.45 (2029) with negative or flat ROI (-0% to -5.4%). From 2030 onward, the forecast turns bullish with higher averages and positive ROIs, including 2030 at 32.6%.
Yes. The forecast shows higher price points later in the horizon: 2040 max is $13.24 and 2050 max is $31.85, with 2030 max at $7.66. This indicates potential to surpass $10 by 2040 in the max scenario and significantly higher by 2050.
Current price is $3.65 per share and the market cap is $31.71M; the stock rank is 4447.
The 30-day range is $2.81 to $4.73.
BriaCell Therapeutics Corp. Community Discussion
0Share your BriaCell Therapeutics Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.